Short answer
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $60M (up 83.8% year over year) with net income of −$56M.
Q1 2026 key financials · XBRL
- Revenue
- $60M
- +83.8% YoY
- Net income
- −$56M
- −12.4% YoY
- Operating margin
- -87.1%
- EPS (diluted)
- −$0.83
- −2.5% YoY
Source: XBRL data from the RHYTHM PHARMACEUTICALS, INC. (RYTM) Q1 2026 10-Q on SEC EDGAR. USD.
RHYTHM PHARMACEUTICALS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q1 2026 IMCIVREE revenue $60.1M, up 5% sequentially; YoY revenue comparison not provided
- U.S. revenue $36.9M, down 5% sequentially; international revenue $23.2M, up $4.9M or 27%
- Net loss $55.6M vs $49.5M YoY; net-loss margin percentages not provided
- Cash, equivalents and short-term investments $340.6M; funding expected for at least 24 months
- PMDA decision expected second half 2026; potential Japan launch by year-end 2026
Risk Factors
- Net loss $55.6 million and accumulated deficit $1,407.5 million increase funding and profitability risk
- Cash and short-term investments $340.6 million, with additional capital potentially needed for expanding clinical programs
- RIFA requires minimum payments by March 31, 2027 and March 31, 2029, potentially constraining operating cash flow
- Phase 3 results may fail to confirm earlier setmelanotide findings, delaying approvals for additional indications
- Uninsured deposits at financial institutions could become inaccessible after an institutional failure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RHYTHM PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.